Single-incision laparoscopic endorectal pull-through for Hirschsprung disease: a prospective institutional study and systematic review with meta-analysis

单切口腹腔镜直肠内拖出术治疗先天性巨结肠:一项前瞻性机构研究和系统评价及荟萃分析

阅读:1

Abstract

BACKGROUND: Single-incision laparoscopic endorectal pull-through (SILEP) has emerged as an alternative to conventional laparoscopic surgery for Hirschsprung disease (HSCR), offering improved cosmetic outcomes with comparable efficacy. However, its adoption remains limited, and evidence supporting its long-term safety and functional outcomes is sparse. This study presents our institutional experience with SILEP, alongside a systematic review and meta-analysis evaluating perioperative outcomes, postoperative complications, bowel function, and cosmesis. PATIENTS AND METHODS: A prospective study was conducted at our institution involving 93 pediatric patients diagnosed with HSCR, who underwent SILEP between 2020 and 2021. Demographic data, perioperative details, and postoperative outcomes, including bowel function score (Rintala) and cosmetic results (Manchester Scar Scale), were prospectively collected and analyzed. Additionally, a systematic review and meta-analysis were performed following PRISMA guidelines, pooling data from nine studies comprising 420 patients. RESULTS: The mean operative time was 70.0 ± 30.3 min, significantly shorter than the pooled estimate from the meta-analysis (166.44 min; 95% CI 137.74-195.14, p < 0.001). No intraoperative complications or conversions were recorded. The mean hospital stay was 5.23 ± 2.69 days, consistent with prior reports. Enterocolitis occurred in 16.1% of cases, comparable to the pooled estimate (12%; 95% CI 7-21%). Among patients aged ≥ 4 years (n = 64), 84% achieved good to excellent bowel function scores. The mean Manchester Scar Score was 5.73 ± 1.38. CONCLUSION: SILEP is a safe, effective, and cosmetically superior approach for HSCR, with favorable perioperative outcomes and functional results. Our findings, supported by meta-analysis data, reinforce the feasibility of SILEP as a viable alternative for HSCR management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。